secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2025-04-23T23:59:59+00:00
Accession:  0001104659-25-038041
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa approves KPL-387 LTIP for execs, grants PSUs and options tied to BLA submission and FDA approval
--------------------------------------------------------------------------------

- Compensation Committee approved KPL-387 Long-Term Incentive Plan for executive officers, linked to BLA submission (Milestone 1) and FDA approval (Milestone 2) for recurrent pericarditis treatment.
- CEO Sanj Patel granted 16,312 PSUs and 26,142 options; CFO Mark Ragosa granted 9,309 PSUs and 14,918 options.
- Awards include cash, PSUs, and options, with earnout percentages (100%, 75%, 50%, 0%) based on milestone achievement dates.
- If a change in control occurs, unvested awards may accelerate under specified conditions, including termination without cause or resignation for good reason.
- The plan covers five named executive officers; cash award amounts are based on base salary at milestone achievement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/0001104659-25-038041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-038041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer